| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.05.
| Johnson & Johnson Setback Is Positive for Pfizer, Bristol-Myers | | 6 | Minyanville |
| 24.05.
| Bristol-Myers Squibb to Take Part in Sanford Bernstein's 28th Annual Strategic Decisions Conference | | 43 | Business Wire |
| Bristol-Myers
Squibb Company (NYSE: BMY) will take part in Sanford Bernstein's
28th Annual Strategic Decisions Conference on Thursday, May 31, 2012, in
New York....
Mehr lesen zu:
Bristol-Myers Squibb to Take Part in Sanford Bernstein's 28th Annual Strategic Decisions Conference | |
| 24.05.
| Plan to Speed Up FDA Reviews for New Drugs and Medical Devices Moved to Senate / Five Star Equities Provides Stock Research on Bristol Myers Squibb and Pfizer | | 47 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/24/12 -- Lost revenues as a result of expiring patents have been a growing problem for the big pharmaceutical companies. New products that are being introduced into...
Mehr lesen zu:
Plan to Speed Up FDA Reviews for New Drugs and Medical Devices Moved to Senate / Five Star Equities Provides Stock Research on Bristol Myers Squibb and Pfizer | |
| 22.05.
| The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr. Reddy's Laboratories | | 76 | PR Newswire |
| CHICAGO, May 22, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr. Reddy's Laboratories | |
| 21.05.
| The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutical, Biogen Idec and Elan | | 56 | PR Newswire |
| CHICAGO, May 21, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers Squibb, Teva Pharmaceutical, Biogen Idec and Elan | |
| 21.05.
| Bristol-Myers Squibb's Thud Heard Round the World | | 3 | Motley Fool |
| 17.05.
| New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting | | 41 | Business Wire |
| Ten Oral Presentations Underscore Breadth and Diversity of
Company's Oncology Portfolio
New Data on YERVOY® (ipilimumab)
and the Investigational...
Mehr lesen zu:
New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting | |
| 16.05.
| FDA approves Bristol-Myers biologics manufacturing facility in Devens | | 1 | Pharma Bus Review |
| 15.05.
| Bristol-Myers says FDA clears Mass. plant | | 1 | Yahoo-USA |
| 15.05.
| FDA Approves Bristol-Myers' Devens Facility For Production Of Orencia | | 57 | AFX News |
| NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) said Tuesday that
the U.S. Food and Drug Administration has approved its biologics manufacturing
facility in Devens, Massachusetts...
Mehr lesen zu:
FDA Approves Bristol-Myers' Devens Facility For Production Of Orencia | |
| 15.05.
| Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture of ORENCIA | | - | StreetInsider.com |
| 15.05.
| U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility | | 1 | Benzinga.com |
| 15.05.
| U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept) | | 16 | Business Wire |
| State-of the art Manufacturing Facility Supports Company's Growing
Focus on Biologics
Bristol-Myers
Squibb Company (NYSE:BMY) announced today...
Mehr lesen zu:
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept) | |
| 15.05.
| Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India | | 32 | Business Wire |
| Initial grant to Shanghai Charity Foundation will help improve
type 2 diabetes care in China's largest city
The Bristol-Myers Squibb Foundation...
Mehr lesen zu:
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India | |
| 15.05.
| The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb | | 46 | PR Newswire |
| CHICAGO, May 15, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb | |
| 15.05.
| Bristol-Myers, Tsinghua University sign multi-year strategic partnership | | - | Pharma Bus Review |
| 15.05.
| Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership | | 78 | Business Wire |
| Bristol-Myers
Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China,
today announced the formation of a multi-year strategic partnership.
...
Mehr lesen zu:
Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership | |
| 14.05.
| Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | | 36 | Business Wire |
| Results of a head-to-head study comparing two biologic drugs on a
background of methotrexate for the treatment of moderate to severe
rheumatoid arthritis to be presented
Bristol-Myers...
Mehr lesen zu:
Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | |
| 14.05.
| Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | | 90 | news aktuell |
| Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to...
Mehr lesen zu:
Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | |
| 14.05.
| Bristol-Myers Squibb to Present New Data on ORENCIA(R) (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | | 25 | PR Newswire |
| PARIS, May 14, 2012 /PRNewswire/ --
Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritisto...
Mehr lesen zu:
Bristol-Myers Squibb to Present New Data on ORENCIA(R) (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress | |
